Linearis

Feldan Therapeutics is a biopharmaceutical company focused on developing innovative treatments using its proprietary peptide-based technology platform, known as the Feldan Shuttle. This platform facilitates fast and safe intracellular delivery, allowing access to cellular components that are typically unreachable by conventional drugs. By leveraging the unique characteristics of the Feldan Shuttle, the company aims to create a new generation of therapeutic applications, as evidenced by its ongoing pipeline of clinical programs. Feldan Therapeutics is committed to advancing the field of intracellular therapeutics to improve patient outcomes.

Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By leveraging self-supervised learning and integrating human multimodal data, the company aims to enhance the effectiveness and personalization of cancer therapies, thereby improving patient outcomes in oncology.

Zilia is a medical technology company that has developed a non-invasive platform leveraging imaging, spectrometry, and artificial intelligence to measure various biomarkers in the human eye. Its flagship product, Zilia Ocular, is the first retinal camera capable of quantifying oxygen saturation, an essential biomarker for assessing ocular diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration. By providing actionable data on the eye's metabolic activity, Zilia aims to enhance the prevention, diagnosis, and management of these conditions. The technology integrates devices, software, and data management to deliver insights into the metabolic and pathophysiological processes of ocular tissues, capitalizing on the eye's optical properties and its connections to the vascular system and brain. This innovation supports researchers and healthcare professionals in monitoring eye health and disease progression.